Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Concordia Healthcare Corp. T.CXR.R

Healthcare Biotechnology


TSX:CXR.R - Post by User

Concordia Healthcare Corp. > Valeant Salix
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Post by ryehigh2014on Nov 01, 2016 9:50pm
182 Views
Post# 25413519

Valeant Salix

Valeant SalixAnyone have any opinions on this? This is HUGE for VRX if they seal the deal. Basically unwinding. 

Curious however:
- Salix has $900MM Expected EBITDA for 2017 
- Its IBS drug Xifafen has competition 
- Its portfolio is also subject to regulatory risk and political risk

So if Takeda sees value despite this than the pharma sector obviously has value. Thoughts on Salix anyone?







<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities